P J Saylor

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer
    Philip J Saylor
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA Electronic address
    Eur Urol 65:642-9. 2014
  2. pmc New and emerging therapies for bone metastases in genitourinary cancers
    Philip J Saylor
    Massachusetts General Hospital, Medicine, Division of Hematology Oncology, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA
    Eur Urol 63:309-20. 2013
  3. doi Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Urol 189:S34-42; discussion S43-4. 2013
  4. pmc Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 18:3677-85. 2012
  5. pmc Bone health and prostate cancer
    P J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Prostate Cancer Prostatic Dis 13:20-7. 2010
  6. pmc Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Natl Compr Canc Netw 8:211-23. 2010
  7. pmc Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Lawrence House POB, 55 Fruit Street, Boston, MA 02114, USA
    J Gen Intern Med 24:S389-94. 2009
  8. ncbi New treatments for renal cell carcinoma: targeted therapies
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Natl Compr Canc Netw 7:645-56. 2009
  9. pmc Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 181:1998-2006; discussion 2007-8. 2009
  10. pmc Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 186:482-6. 2011

Detail Information

Publications15

  1. doi Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer
    Philip J Saylor
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA Electronic address
    Eur Urol 65:642-9. 2014
    ..Each is a risk factor for gallstone disease. Additionally, GnRH agonist treatment was recently shown in metabolomic analyses to increase plasma levels of some bile acids...
  2. pmc New and emerging therapies for bone metastases in genitourinary cancers
    Philip J Saylor
    Massachusetts General Hospital, Medicine, Division of Hematology Oncology, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA
    Eur Urol 63:309-20. 2013
    ..Bone metastases are a common feature of advanced genitourinary malignancies and a prominent cause of morbidity and mortality...
  3. doi Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Urol 189:S34-42; discussion S43-4. 2013
    ....
  4. pmc Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 18:3677-85. 2012
    ..It is unknown what other metabolic alterations are caused by ADT. To better characterize the metabolic effects of ADT, we measured changes in plasma metabolomic profile at baseline and after the first 3 months of therapy...
  5. pmc Bone health and prostate cancer
    P J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Prostate Cancer Prostatic Dis 13:20-7. 2010
    ..In the absence of a prostate cancer-specific algorithm, we advocate the use of FRAX for men receiving ADT...
  6. pmc Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Natl Compr Canc Netw 8:211-23. 2010
    ..Currently the authors advocate the use of adapted practice guidelines developed to prevent diabetes, fractures, and coronary heart disease in the general population...
  7. pmc Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Lawrence House POB, 55 Fruit Street, Boston, MA 02114, USA
    J Gen Intern Med 24:S389-94. 2009
    ..This population of mostly older men is medically vulnerable to a variety of treatment-associated adverse effects...
  8. ncbi New treatments for renal cell carcinoma: targeted therapies
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Natl Compr Canc Netw 7:645-56. 2009
    ..Finally, postnephrectomy adjuvant treatment with targeted agents is not yet standard but is under investigation in phase III trials...
  9. pmc Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 181:1998-2006; discussion 2007-8. 2009
    ....
  10. pmc Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 186:482-6. 2011
    ..We evaluated risk factors associated with vertebral fractures among men enrolled in a fracture prevention trial...
  11. pmc Emerging therapies to prevent skeletal morbidity in men with prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA
    J Clin Oncol 29:3705-14. 2011
    ....
  12. pmc Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Urol 183:2200-5. 2010
    ..We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer...
  13. pmc Contemporary therapeutic approaches targeting bone complications in prostate cancer
    Richard J Lee
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, 02114, USA
    Clin Genitourin Cancer 8:29-36. 2010
    ..Data from recent phase III clinic trials demonstrate the emerging role for denosumab in the treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy...
  14. pmc Treatment and prevention of bone complications from prostate cancer
    Richard J Lee
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Bone 48:88-95. 2011
    ..Recent global phase 3 clinic trials demonstrated an emerging role for denosumab in the treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy...
  15. ncbi Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
    Philip J Saylor
    Department of Oncology, University of California, San Diego, CA, USA
    J Clin Oncol 25:3544-6. 2007